Gan & Lee Pharmaceuticals has entered an exclusive licence agreement with JW Pharmaceutical for the commercialisation of bofanglutide injection in South Korea.

Roche has signed a new collaboration deal with C4 Therapeutics to jointly advance DACs research to introduce a new therapeutic modality for cancer.

Shionogi will use the money from BARDA to build an American antibiotic manufacturing site as the US looks to fight antimicrobial resistance.

Biomarkers are revolutionizing oncology drug development, driving modern precision medicine approaches, targeted clinical trial recruitment strategies, and critical decision-making.

Global independent private equity fund Jeito Capital has closed its second fund, Jeito II, surpassing its target of €1bn ($1.2bn).

The rare disease framework has had a turbulent past few years, with the FDA looking to create regulatory stability.

Everest Medicines’ wholly owned subsidiary EverSea Medicines (Singapore) has signed a share purchase agreement to conditionally acquire Hasten Biopharmaceuticals, a subsidiary of Hasten ...

Otsuka Pharmaceutical is to fully acquire Transcend Therapeutics via its subsidiary Otsuka America for a potential ...

The funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress its bispecific ADC programmes to the clinic.

Apnimed has signed a senior secured credit facility of up to $150m with funds managed by HCRx to support the planned launch of AD109.

Sixteen months after partnering with Tubulis, Gilead has decided to acquire the biotech and its portfolio of ADCs.

As ADC pipelines expand rapidly, innovations in payload linker chemistry are becoming a key enabler of next-generation ...